Searched for
RLL SHARES
Motilal Oswal predicts 35% upside in Raymond Lifestyles, initiates coverage with ‘buy’ ratingMotilal Oswal has begun coverage of Raymond Lifestyle (RLL) with a buy rating and a target price of Rs 3,200, anticipating a transformative...21 Oct, 2024, 01.15 PM IST- Raymond Lifestyle shares list at Rs 3,020 on NSE after demergerRaymond Lifestyle Share Price: Raymond Lifestyle, which demerged from Raymond Ltd in June, began trading on the stock exchanges today. The ...05 Sep, 2024, 11.44 AM IST
- Raymond shares surge 8% in 2 days ahead of lifestyle business’ listing tomorrowRaymond Share Price: Raymond's shares rose by 8% over two days, reaching Rs 2,179 on the BSE. This surge comes ahead of the listing of its ...04 Sep, 2024, 12.05 PM IST
- Raymond shares jump 9% ahead of listing of lifestyle business. Here's whyRaymond Share Price: Raymond shares jumped 9% to Rs 2,182 ahead of its lifestyle business listing this week. Brokerages, including Motilal ...03 Sep, 2024, 04.54 PM IST
- Raymond Lifestyle onboards top guns ahead of likely IPORaymond Lifestyle appointed Vineet Nayar, GC Chaturvedi, Anisha Motwani, and Dinesh Lal as directors. Gautam Singhania is likely MD, with S...14 Jul, 2024, 11.53 PM IST
- Raymond shares trade ex-lifestyle business, stock jumps over 4%Raymond's lifestyle business demerger process begins with shareholders receiving new equity shares. The company's stock price rises by near...11 Jul, 2024, 12.06 PM IST
- Ranbaxy launches anti-acne drug in the US marketAccording to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...26 Nov, 2012, 02.26 PM IST
- HDFC recommends 'sell' on Ranbaxy for target of Rs 230HDFC Securities has downgraded Ranbaxy Laboratories (RLL) from Hold to “Sell” with a price target of Rs 230 per share in its post-result up...03 Mar, 2010, 11.09 AM IST
- CARE assigns 'PR1+' to bank loan facilities of RanbaxyCARE assigned 'PR1+' rating to the short term bank facilities availed by Ranbaxy Laboratories Ltd.04 Jul, 2008, 10.48 AM IST
- Lupin buys Baroda co RubaminRLL, a subsidiary of the Rubamin group, manufactures advanced intermediates and Active Pharmaceutical Ingredients (APIs) and provides resea...28 Sep, 2007, 12.33 AM IST
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.27 Sep, 2007, 12.15 PM IST
- Ranbaxy launches 'Storvas' in MalaysiaThe company has received approvals from the Drugs Control Authority of Malaysia to manufacture and market the products.27 Sep, 2006, 04.10 PM IST
Load More
